Investors

Press Releases

Press Releases

December 22, 2020
Allakos Appoints Natalie Holles to its Board of Directors
REDWOOD CITY, Calif. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles , president and chief executive officer of
October 28, 2020
Allakos Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif. , Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering.
October 27, 2020
Allakos Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif. , Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and other conditions, $250
October 21, 2020
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
REDWOOD CITY, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-blind,
Displaying 1 - 10 of 20


(Common Stock)


February 12, 2021 11:15 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.